SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvells all-stock agreement to acquire Lumentum has triggered a sharp selloff, with many traders criticizing the deals cost, shareholder dilution and long wait for completion. Others argue the combination could strengthen Marvells position in optical connectivity for AI data centers over the long term.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is under pressure as Intels disappointing results and outlook have unsettled semiconductor investors, while broader concerns about AI spending and elevated valuations add to the selloff ahead of AMDs earnings. Traders are divided over whether the decline is sympathy selling that AMD can overcome or a warning sign, with the companys results and guidance seen as key tests.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Marvells agreed all-stock acquisition of Lumentum dominates discussion, with LITE holders concerned that the fixed exchange ratio ties their value to Marvells share price through a lengthy closing process. Traders debate the strategic fit in AI optics against dilution, the deals terms, and whether the transaction will win shareholder approval; some see long-term potential while many criticize the near-term reaction.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

A sharp selloff has traders focused on Usonas competing NDA filing and Compass Pathways still-pending completion of its own NDA, with investors looking to the upcoming earnings update for a clearer filing timeline. Some see Usona as a competitive threat and fault Compass management for delays, while others say the news was known and the drop reflects broader biotech weakness or an overreaction.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples fiscal Q4 earnings and outlook dominate discussion, with traders focused on holiday-quarter iPhone demand and whether rising memory costs will pressure margins. Views are split between bulls expecting strong results and bears arguing that the stocks strong run and high valuation leave it vulnerable to a selloff, with the report also seen as a key test for broader tech sentiment.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is selling off alongside semiconductor and AI-related stocks as traders question whether AI spending and memory demand can sustain their recent pace; Kioxias cautious outlook has reinforced concerns about memory pricing and a possible cyclical slowdown. The debate pits those worries against bullish views that AI-driven demand and tight memory supply remain strong.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellass REGAL Phase 3 AML trial reaching its 80-event trigger and moving to final analysis is driving attention ahead of topline results. Traders are split over the sharp selloff: some blame short-term positioning, while others worry it signals weak results; claims of a data leak remain speculation.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCIs upcoming quarterly report is the dominant focus, with traders weighing strong preliminary revenue and margin guidance against concerns about cash flow, inventory, and whether the results can restore investor confidence. The shares sharp decline despite the upbeat preview has split the community between dip-buyers anticipating a rebound and skeptics who expect weak cash conversion or guidance to weigh on the stock; broader weakness in AI and tech stocks is also cited.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels weaker-than-expected fourth-quarter outlook, with supply constraints and softer PC demand weighing on expectations, sparked a steep post-earnings selloff. Traders are split between viewing the decline as an overreaction and expecting further downside, with many citing the companys execution and foundry prospects as key uncertainties.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisks sharp post-earnings selloff, despite a strong report and raised outlook, is dominating discussion. Traders point to Kioxias cautious NAND outlook and broader semiconductor weakness as signs that memory-price growth or AI demand could cool, while bulls argue that long-term storage demand and SanDisks fundamentals remain strong.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ADIL Stock Eyes Best Day In Over 5 Years — Major Pipeline Overhaul And $64M Raise Fuel Rally

Equity

Adial on Thursday announced that it has bought privately held Azora Therapeutics.

Adial Pharmaceuticals Applies For FDA Priority Voucher Program For AD04

(RTTNews) - Adial Pharmaceuticals, Inc. (ADIL) on Monday said it has submitted its AD04 application for consideration under the U.S. Food and Drug Administration Commissioner's National Priority Voucher Pilot Program (CNPV...

Adial Pharmaceuticals Lead Drug Fits New Policy Mood As Bipartisan Bill Signals Broader Lens On Alcohol Use Disorder

Adial backs H.R. 7091 targeting AUD in veterans, spotlighting harm reduction therapies and expanding research beyond abstinence-based care.read more...

Why Did Adial Pharmaceuticals Stock Plunge Over 20% After Hours Today?

The reverse split is intended to bring the company back into compliance with Nasdaq’s $1 minimum bid price rule.

Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?

Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.

All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy

Adial Pharmaceuticals (ADIL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Adial Pharmaceuticals (ADIL) Upgraded to Strong Buy: Here's Why

Adial Pharmaceuticals (ADIL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Retail Traders Flock To Adial Pharma After Patent News Sends Shares Soaring

Adial Pharmaceuticals jumped to its highest level since February after receiving a U.S. patent for its precision medicine approach to treating addiction. The patent supports the use of AD04 in patients with specific genetic markers.

Azora Therapeutics, Inc. is a biopharmaceutical company that develops therapies for immune-mediated inflammatory diseases. Its investigational oral drug, AT177, is being develop for inflammatory bowel diseases, with an initial focus on ulcerative colitis. The company was founded by Julie Saiki and Matthew Davidson which is headquartered in Los Angeles, CA.

Adial Pharmaceuticals Inc

Bullish Sentiment

<ul class="summary-bullets"><li>The main goal of the deal is to bring Azora’s lead drug candidate, called AT177, into Adial’s pipeline.</li><li>Adial expects to begin the first human clinical trial for the experimental drug in mid-2027.</li><li>The firm is also raising up to $64 million in total through private financing as part of the deal.</li></ul>Shares of Adial Pharmaceuticals, Inc. (ADIL) jumped as much as 110% after the company announced the acquisition of privately held Azora Therapeutics, Inc., a biopharmaceutical company developing treatments for inflammatory diseases, in a transaction accompanied by up to $64 million in gross proceeds from a concurrent private placement financing.The stock is now on track for its best day since September 2020, if gains hold.The main goal of the deal is to bring Azora’s lead drug candidate, called AT177, into Adial’s pipeline. AT177 is an experimental once-daily pill designed to treat ulcerative colitis by working directly in the colon to reduce inflammation, while limiting effects on the rest of the body.The drug is currently in the final stages of lab and animal testing needed before it can be tested in humans. Adial expects to begin the first human clinical trial in mid-2027.The transaction marks a shift for Adial, which focuses on addiction treatments.<h2 class="st-heading-2">Terms Of The Deal</h2>Under the deal, Azora’s shareholders will receive Adial stock. After the transaction closes, former Azora shareholders will own about 51% of the combined company, current Adial shareholders about 8%, and new investors putting money into the financing about 41%. The deal has already been approved by both companies’ boards and by Azora’s shareholders. Adial will still need approval from its own shareholders for certain parts of the deal, which it plans to seek soon.Adial is also raising up to $64 million in total through private financing as part of the deal. Approximately $32 million will be invested immediately, while the remaining $32 million will be released once the company successfully begins its first human clinical trial of AT177. Proceeds will be used primarily to fund development of AT177 and initiate early-stage clinical studies, the company said.<h2 class="st-heading-2">How Did ADIL Retail Traders React?</h2>On Stocktwits, retail sentiment around ADIL stock jumped from ‘neutral’ to ‘bearish’ over the past 24 hours, while message volume stayed at ‘normal’ levels.A Stocktwits user termed the news “perfect” and expressed optimism for the stock rallying on Friday as well.<stembedurl>https://www.stocktwits.com/AtillaB/message/656149262</stembedurl>Another, however, expressed doubts about the deal.<stembedurl>https://www.stocktwits.com/fastmoneytraders/message/656149353</stembedurl>According to data from Koyfin, both analysts covering ADIL rate it ‘Buy’ or higher. The stock has a 12-month average price target of $25, which represents a potential upside of over 1000% from the stock’s last close.<a href="https://stocktwits.com/symbol/ADIL">ADIL stock</a> has fallen 39% over the year.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ttd-stock-in-spotlight-after-firm-ropes-in-zendesk-marketing-chief-retail-hopes-new-hires-turn-things-around-at-trade-desk/cZKTDdaR728">TTD Stock In Spotlight After Firm Ropes In Zendesk Marketing Chief – Retail Hopes New Hires Turn Things Around At Trade Desk</a>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, the Adial Pharmaceuticals logo is displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Vanguard Extended Market ETF

Up more than 3%

Flat to up 3%

Flat to down 3%

Down more than 3%

What’s your expected total return for the S&amp;P 500 ($SPY) in November?

Stocktwits

What’s your expected total return for the S&P 500 (

Current Price	$3.92
Prev Close	$3.81
Open	$4.29
Dividend Yield	0.00%
50-Day Moving Average	$4.69
Beta	0.71
Avg. Volume	47,372.56
PE Ratio	-0.23

52-Week High	$8.75
52-Week Low	$1.31
Market Capitalization	$10M
EPS (Annual)	-$11.93
Price to Book	-0.26
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

ADIL Fundamentals